亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy and Safety of Early Initiation of Sodium-Glucose Cotransporter 2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta-Analysis

医学 心力衰竭 不利影响 达帕格列嗪 重症监护医学 急性肾损伤 急性失代偿性心力衰竭 随机对照试验 内科学 临床试验 系统回顾 肾功能 心脏病学 梅德林 肿瘤科 肾 荟萃分析 肾脏疾病 药理学
作者
Emídio Mata,B L Resende,Margarida Castro,João Português,Sílvia Ribeiro,João Gameiro,António Lourenço,L Goncalves
出处
期刊:Sunhwan'gi 卷期号:56 被引量:1
标识
DOI:10.4070/kcj.2025.0466
摘要

BACKGROUND AND OBJECTIVES: Acute heart failure (AHF) remains associated with high short-term mortality and rehospitalization despite advances in therapy. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) provide robust cardiovascular benefits in heart failure, but their efficacy and safety when initiated during AHF hospitalization are less established. METHODS: Following a systematic search of 4 databases, a systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to evaluate the efficacy and safety of the initiation of dapagliflozin or empagliflozin during hospitalization for AHF, in addition to standard therapy. The primary outcome was all-cause mortality. Secondary outcomes included heart failure hospitalization (HFH), all-cause mortality at 1 month, cardiovascular death, serious adverse events leading to drug discontinuation, acute kidney injury (AKI), urinary tract infection (UTI), symptomatic hypotension, hypoglycemia, and diabetic ketoacidosis. Data were pooled using random-effects models, with sensitivity and meta-regression analyses. RESULTS: Eight RCTs including 3,596 patients (1,817 SGLT2i; 1,779 control) were analyzed. SGLT2i initiation in AHF significantly reduced all-cause mortality (risk ratio [RR], 0.63; confidence interval [CI], 0.46-0.85; I²=0%) and all-cause mortality at 1 month (RR, 0.75; CI, 0.57-0.98; I²=0%). HFH and cardiovascular death did not differ significantly between groups. Pooled analyses showed no excess risk of serious adverse events leading to drug discontinuation, AKI, UTI, symptomatic hypotension, hypoglycemia or ketoacidosis. CONCLUSIONS: Initiation of SGLT2i during AHF hospitalization significantly improves survival without increasing adverse safety events, supporting their use as an early guideline-directed therapy. The absence of a clear effect on HFH highlights the need for further large-scale and patient-level analyses. TRIAL REGISTRATION: PROSPERO Identifier: CRD420251140155.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
Yh发布了新的文献求助30
3秒前
3秒前
CMJ完成签到,获得积分10
3秒前
大个的应助被儒雅傲人采纳,获得10
4秒前
小马甲的应助被儒雅傲人采纳,获得10
4秒前
6秒前
Xenomorph发布了新的文献求助50
6秒前
小棉发布了新的文献求助10
7秒前
辛勤的涵菡完成签到,获得积分10
7秒前
Hello的应助被Brightfuture采纳,获得10
8秒前
风趣含双发布了新的文献求助10
9秒前
13秒前
16秒前
所所的应助被可乐采纳,获得10
18秒前
pengua发布了新的文献求助10
20秒前
yizimm完成签到 ,获得积分10
20秒前
23秒前
Lusteri完成签到 ,获得积分10
24秒前
板栗炒鸡完成签到,获得积分10
27秒前
28秒前
28秒前
畅快怜容完成签到,获得积分20
29秒前
敏感一一完成签到,获得积分10
30秒前
32秒前
32秒前
怡然的扬发布了新的文献求助10
35秒前
36秒前
Brightfuture发布了新的文献求助10
36秒前
37秒前
37秒前
Baldwin完成签到 ,获得积分10
38秒前
玖嬴完成签到,获得积分10
39秒前
soilman发布了新的文献求助10
41秒前
传奇3的应助被虚幻的凌珍采纳,获得10
41秒前
灵剑山发布了新的文献求助10
47秒前
soilman完成签到,获得积分10
47秒前
小二郎的应助被樱桃小丸子采纳,获得10
49秒前
小棉完成签到,获得积分10
50秒前
善良的金鱼完成签到,获得积分10
51秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172954
求助须知:如何正确求助?哪些是违规求助? 9565479
关于积分的说明 21780097
捐赠科研通 7764853
什么是DOI,文献DOI怎么找? 3431513
关于科研通互助平台的介绍 2555530
邀请新用户注册赠送积分活动 2476595